Table 8.
Reasons to start/stop therapy with golimumab and adverse events upon treatment with golimumab.
| Reasons to start golimumab a | N = 103 |
|---|---|
| Active disease | 78 (75.7%) |
| Intestinal activity | 72 (69.9%) |
| EIMs | 6 (5.8%) |
| Side effect of previous drugs | 9 (8.7%) |
| Antibodies against previous TNF inhibitors | 9 b (8.7%) |
| Prevention of flare | 1 (1%) |
| Unknown | 14 (13.6%) |
| Reasons to stop golimumab | N = 103 |
| Primary non-response | 24 (23.3%) |
| Loss of response | 16 (15.5%) |
| Side effects | 8 c (7.8%) |
| Patients’ preference | 2 (1.9%) |
| Pregnancy | 1 (1%) |
| Unknown | 25 (24.3%) |
| Ongoing at the time of chart review | 27 (26.2%) |
| Adverse events a | |
| Dizziness | 4 |
| Fever | 2 |
| Psoriasis | 2 |
| Hair loss | 2 |
| Common cold or cough | 2 |
| Combination of symptoms | 4 |
| Problems breathing, fatigue, dizziness, dry eyes | 1 |
| Dizziness, malaise, weakness, fever | 1 |
| Dizziness, bloating, nausea, headache | 1 |
| Dizziness, visual problems, swollen legs, and hair loss | 1 |
| Meningitis | 1 |
EIM, extraintestinal manifestation; TNF, tumor necrosis factor.
a
More than one could be mentioned.
b
Eight against infliximab, one against adalimumab.
c
Four combined with primary non-response and one with secondary non-response.